597 641

Cited 39 times in

Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer

DC Field Value Language
dc.contributor.author문용화-
dc.contributor.author박무석-
dc.contributor.author손주혁-
dc.contributor.author정경영-
dc.contributor.author김세규-
dc.contributor.author김주항-
dc.date.accessioned2014-12-21T16:28:47Z-
dc.date.available2014-12-21T16:28:47Z-
dc.date.issued2007-
dc.identifier.issn0008-543X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/95770-
dc.description.abstractBACKGROUND: The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer (NSCLC). METHODS: The authors performed an in vitro chemosensitivity test, ATP-CRA, to evaluate the chemosensitivities of anticancer drugs such as cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine for chemonaive, unresectable NSCLC. The cell death rate was determined by measuring the intracellular ATP levels of drug-exposed cells compared with untreated controls. A sensitive drug was defined as a drug producing 30% or more reduction in ATP compared with untreated controls. Assay-guided platinum-based 2-drug chemotherapy was given to patients with pathologically confirmed NSCLC. RESULTS: Thirty-four patients were enrolled. Thirty tumor specimens were obtained by bronchoscopic biopsies and 4 obtained surgically. The median age was 61 years and 27 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The response rate was 43.8%. At a median follow-up period of 16.9 months, the median progression-free and overall survivals were 3.6 and 11.2 months, respectively. Patients were dichotomized into the platinum-sensitive (S; 20 patients) and resistant (R; 14 patients) groups. The positive/negative predictive values were 61.1% and 78.6% with a predictive accuracy of 68.8%. Although without significant differences in pretreatment parameters, the S-group showed better clinical response (P=.036), longer progression-free survival (P=.060), and longer overall survival (P=.025). CONCLUSIONS: Despite using bronchoscopic biopsied specimens, ATP-CRA and clinical outcomes correlated well after assay-guided platinum-based 2-drug chemotherapy for unresectable NSCLC. There was a favorable response and survival in the platinum-sensitive vs resistant groups.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.relation.isPartOfCANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleAdenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery (흉부외과학)-
dc.contributor.googleauthorYong Wha Moon-
dc.contributor.googleauthorSung Ho Choi-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorHyoun Ju Lee-
dc.contributor.googleauthorKyung Young Chung-
dc.contributor.googleauthorMoo Suk Park-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorYong Tai Kim-
dc.identifier.doi10.1002/cncr.22601-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01370-
dc.contributor.localIdA01457-
dc.contributor.localIdA01995-
dc.contributor.localIdA03571-
dc.contributor.localIdA00602-
dc.contributor.localIdA00753-
dc.contributor.localIdA00945-
dc.relation.journalcodeJ00434-
dc.identifier.eissn1097-0142-
dc.contributor.alternativeNameMoon, Yong Wha-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameChung, Kyung Young-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Yong Tai-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.affiliatedAuthorMoon, Yong Wha-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorChung, Kyung Young-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Yong Tai-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.rights.accessRightsfree-
dc.citation.volume109-
dc.citation.number9-
dc.citation.startPage1829-
dc.citation.endPage1835-
dc.identifier.bibliographicCitationCANCER, Vol.109(9) : 1829-1835, 2007-
dc.identifier.rimsid51537-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.